Search Within

Matthew David Hellmann

  1. "Annals of Oncology"
Formats
  1. Journal Article (24)
  2. Meeting Abstract (23)
  3. Editorial (1)
  4. Review (1)
Groups
  1. Department of Medicine (49)
  2. Solid Tumor Oncology Division (49)
  3. Thoracic Oncology (49)
  4. GSK Faculty (12)
  5. Body Imaging Service (8)
  6. Radiology, Department of (8)

More Groups

People
  1. Hira Rizvi (12)
  2. Gregory Riely (8)
  3. Kathryn Arbour (8)
  4. Jamie Chaft (7)
  5. Mark Kris (7)
  6. Andrew Plodkowski (6)

More People

Years
  1. 2023 (1)
  2. 2022 (3)
  3. 2021 (8)
  4. 2020 (7)
  5. 2019 (8)
  6. 2018 (6)

More Years

Publications
  1. Annals of Oncology (49)
Publishers
  1. Oxford University Press (49)

Results (49)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: A pooled analysis
    Journal Article

    Borghaei, H.; Ciuleanu, T. E.; Lee, J. S.; Pluzanski, A.; Caro, R. B.; Gutierrez, M.; Ohe, Y.; Nishio, M.; Goldman, J.; Ready, N.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Impact of intratumoral microbiome on immunotherapy treatment outcomes in patients with advanced non-small cell lung cancer
    Meeting Abstract

    Elkrief, A.; Bowman, A.; Rizvi, H.; Hellmann, M.; Riely, G. J.; Schoenfeld, A. J.; Ladanyi, M.; Vanderbilt, C. M.
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Deciphering radiological stable disease to immune checkpoint inhibitors
    Journal Article

    Luo, J.; Wu, S.; Rizvi, H.; Zhang, Q.; Egger, J. V.; Osorio, J. C.; Schoenfeld, A. J.; Plodkowski, A. J.; Ginsberg, M. S.; Callahan, M. K.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Insights from prospective multi-omic profiling of lymphocytes in resected lung cancer
    Editorial

    Chow, A.; Hellmann, M. D.
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets): Intracranial and systemic outcomes from CheckMate 227 Part 1
    Meeting Abstract

    Reck, M.; Ciuleanu, T. E.; Pluzanski, A.; Lee, J. S.; Bernabe Caro, R.; Linardou, H.; Burgers, J.; Gallardo, C.; Nishio, M.; Peters, S.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) + ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced NSCLC (aNSCLC) in CheckMate 227 part 1: Efficacy by KRAS, STK11, and KEAP1 mutation status
    Meeting Abstract

    Ramalingam, S. S.; Balli, D.; Ciuleanu, T. E.; Pluzanski, A.; Lee, J. S.; Schenker, M.; Caro, R. B.; Lee, K. H.; Bartolucci, R.; Audigier-Valette, C.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Lesion-level heterogeneity of radiologic progression in patients treated with pembrolizumab
    Journal Article

    Topp, B. G.; Thiagarajan, K.; De Alwis, D. P.; Snyder, A.; Hellmann, M. D.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: Phase II of the Friends of Cancer Research TMB Harmonization Project
    Journal Article

    Vega, D. M.; Yee, L. M.; McShane, L. M.; Williams, P. M.; Chen, L.; Vilimas, T.; Fabrizio, D.; Funari, V.; Newberg, J.; Bruce, L. K.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer
    Journal Article

    Schoenfeld, A. J.; Antonia, S. J.; Awad, M. M.; Felip, E.; Gainor, J.; Gettinger, S. N.; Hodi, F. S.; Johnson, M. L.; Leighl, N. B.; Lovly, C. M.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Early circulating tumour DNA (ctDNA) dynamics for predicting and monitoring response to immunotherapy (IO) vs chemotherapy (CT) in patients with 1L metastatic (m) NSCLC: Analyses from the phase III MYSTIC trial
    Meeting Abstract

    Peters, S.; Rizvi, N. A.; Kuziora, M.; Lai, Z.; Shrestha, Y.; Dey, A.; Barrett, J. C.; Scheuring, U.; Poole, L.; Abbosh, C.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save